FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386837112> ?p ?o ?g. }

• W4386837112 endingPage "8476" @default.
• W4386837112 startingPage "8464" @default.
• W4386837112 abstract "The present study aimed to investigate the influence of the mutation abundance of the epidermal growth factor receptor (EGFR) and its co-mutation with TP53 on the therapeutic efficacy of tyrosine kinase inhibitor (TKI) treatment in patients with metastatic lung adenocarcinoma (LUAD). In total, 130 patients (January 2018-September 2022) with metastatic LUAD from the Second Affiliated Hospital of Zhejiang University were included. Kaplan-Meier analysis was performed to measure the duration of drug application (DDA) and the log-rank test was used to compare differences. Univariate and multivariate analyses of Cox proportional hazard regression models were used to evaluate the association between the relevant clinicopathological factors and DDA. Hazard ratios with 95% confidence intervals were also calculated. Among the 130 patients who were treated with first-generation EGFR-TKIs, 86 showed high-EGFR mutation abundance (>22.0%) and 44 showed low-EGFR mutation abundance (≤22.0%). Patients in the high-EGFR group had a greater DDA than those in the low-EGFR group (p < 0.05). The results of the subgroup analysis were consistent with those of the total mutation population (exon19: >18.5% vs. ≤18.5%, 14 months vs. 10 months, p = 0.049; exon21: >22.0% vs. ≤22.0%, 15 months vs. 9 months, p = 0.005). In addition, the mutation abundance of TP53 was negatively correlated with the DDA (p < 0.05). Patients in the combination group had a better DDA than those in the monotherapy group (p < 0.05). Subgroup analysis showed that, among the low mutation abundance of the EGFR exon 21 or 19 cohort, the combination group had a better DDA than the monotherapy group (p < 0.05). An EGFR mutation abundance greater than 22.0% was a positive predictor of DDA in patients with metastatic LUAD. However, a TP53 mutation abundance higher than 32.5% could reverse this situation. Finally, first-line treatment with EGFR-TKIs plus chemotherapy is a potential treatment strategy for patients with low-abundance EGFR mutations." @default.
• W4386837112 created "2023-09-19" @default.
• W4386837112 creator A5001233560 @default.
• W4386837112 creator A5026997847 @default.
• W4386837112 creator A5041338628 @default.
• W4386837112 creator A5091476281 @default.
• W4386837112 date "2023-09-15" @default.
• W4386837112 modified "2023-09-30" @default.
• W4386837112 title "Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer" @default.
• W4386837112 cites W2001727709 @default.
• W4386837112 cites W2103295992 @default.
• W4386837112 cites W2132157071 @default.
• W4386837112 cites W2134897113 @default.
• W4386837112 cites W2139790154 @default.
• W4386837112 cites W2146448515 @default.
• W4386837112 cites W2154969724 @default.
• W4386837112 cites W2160212814 @default.
• W4386837112 cites W2162656203 @default.
• W4386837112 cites W2210071992 @default.
• W4386837112 cites W2289152643 @default.
• W4386837112 cites W2302158695 @default.
• W4386837112 cites W2519152232 @default.
• W4386837112 cites W2550710477 @default.
• W4386837112 cites W2565077351 @default.
• W4386837112 cites W2589106419 @default.
• W4386837112 cites W2624879514 @default.
• W4386837112 cites W2655216406 @default.
• W4386837112 cites W2766316939 @default.
• W4386837112 cites W2775798067 @default.
• W4386837112 cites W2783397995 @default.
• W4386837112 cites W2790465248 @default.
• W4386837112 cites W2792218462 @default.
• W4386837112 cites W2792692302 @default.
• W4386837112 cites W2793089503 @default.
• W4386837112 cites W2794883050 @default.
• W4386837112 cites W2884192683 @default.
• W4386837112 cites W2890614044 @default.
• W4386837112 cites W2898978171 @default.
• W4386837112 cites W2903084459 @default.
• W4386837112 cites W2904314305 @default.
• W4386837112 cites W2946670461 @default.
• W4386837112 cites W2962129043 @default.
• W4386837112 cites W2987053327 @default.
• W4386837112 cites W3015975085 @default.
• W4386837112 cites W3016393959 @default.
• W4386837112 cites W3016720073 @default.
• W4386837112 cites W3105369138 @default.
• W4386837112 cites W3113067628 @default.
• W4386837112 cites W4220879423 @default.
• W4386837112 cites W4280533169 @default.
• W4386837112 cites W4315754639 @default.
• W4386837112 cites W4322754405 @default.
• W4386837112 doi "https://doi.org/10.3390/curroncol30090616" @default.
• W4386837112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37754531" @default.
• W4386837112 hasPublicationYear "2023" @default.
• W4386837112 type Work @default.
• W4386837112 citedByCount "0" @default.
• W4386837112 crossrefType "journal-article" @default.
• W4386837112 hasAuthorship W4386837112A5001233560 @default.
• W4386837112 hasAuthorship W4386837112A5026997847 @default.
• W4386837112 hasAuthorship W4386837112A5041338628 @default.
• W4386837112 hasAuthorship W4386837112A5091476281 @default.
• W4386837112 hasBestOaLocation W43868371121 @default.
• W4386837112 hasConcept C104317684 @default.
• W4386837112 hasConcept C121608353 @default.
• W4386837112 hasConcept C126322002 @default.
• W4386837112 hasConcept C143998085 @default.
• W4386837112 hasConcept C144301174 @default.
• W4386837112 hasConcept C160798450 @default.
• W4386837112 hasConcept C187960798 @default.
• W4386837112 hasConcept C207103383 @default.
• W4386837112 hasConcept C2776256026 @default.
• W4386837112 hasConcept C2779438470 @default.
• W4386837112 hasConcept C2781182431 @default.
• W4386837112 hasConcept C2908647359 @default.
• W4386837112 hasConcept C38180746 @default.
• W4386837112 hasConcept C44249647 @default.
• W4386837112 hasConcept C501734568 @default.
• W4386837112 hasConcept C50382708 @default.
• W4386837112 hasConcept C54355233 @default.
• W4386837112 hasConcept C71924100 @default.
• W4386837112 hasConcept C86803240 @default.
• W4386837112 hasConcept C99454951 @default.
• W4386837112 hasConceptScore W4386837112C104317684 @default.
• W4386837112 hasConceptScore W4386837112C121608353 @default.
• W4386837112 hasConceptScore W4386837112C126322002 @default.
• W4386837112 hasConceptScore W4386837112C143998085 @default.
• W4386837112 hasConceptScore W4386837112C144301174 @default.
• W4386837112 hasConceptScore W4386837112C160798450 @default.
• W4386837112 hasConceptScore W4386837112C187960798 @default.
• W4386837112 hasConceptScore W4386837112C207103383 @default.
• W4386837112 hasConceptScore W4386837112C2776256026 @default.
• W4386837112 hasConceptScore W4386837112C2779438470 @default.
• W4386837112 hasConceptScore W4386837112C2781182431 @default.
• W4386837112 hasConceptScore W4386837112C2908647359 @default.
• W4386837112 hasConceptScore W4386837112C38180746 @default.
• W4386837112 hasConceptScore W4386837112C44249647 @default.
• W4386837112 hasConceptScore W4386837112C501734568 @default.

• next